Karoly Nikolich is an advisor with the Sergey Brin Family Foundation dedicated to new therapies for Parkinson’s disease. He also advises Pivotal BioVentures. During the 1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has also served as a member of the boards of directors and scientific advisory boards of a number of neurotherapeutics and biotech companies. He currently serves as Chair of the Board of Directors at Alkahest, a Grifols company. He has been an Adjunct Professor in the Department of Psychiatry at Stanford University Medical School. He is also a member of the board of the CHS Foundation as well as the Schaller-Nikolich Foundation in Heidelberg, Germany. Karoly is a graduate of Eotvos University in Budapest and worked as a postdoctoral fellow at Tulane University and UCSF before joining Genentech.